Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Established efficacy and safety of dupilumab for atopic dermatitis (AD).
• Limited real-world data on long-term dupilumab effectiveness, safety, and drug survival in AD patients.

Purpose of the Study:

• To evaluate the long-term effectiveness, safety, and drug survival of dupilumab in adult patients with AD in a real-world setting.

Main Methods:

• Retrospective, multicentric, observational study of 312 adult AD patients initiating dupilumab.
• Follow-up up to 30 months, assessing drug survival, adverse events, Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), and Dermatology Life Quality Index (DLQI).

Main Results:

• 30-month drug survival rate of 82.0%.
• Significant improvements observed: EASI (89.3%), pruritus NRS (76.4%), and DLQI (85.2%) at 30 months.
• Most common adverse events were conjunctivitis (17%) and facial erythema (9%); 12.5% discontinued treatment.

Conclusions:

• Dupilumab demonstrates sustained effectiveness and a favorable safety profile for AD management in real-world clinical practice.
• The study contributes valuable data on long-term dupilumab outcomes beyond controlled clinical trials.